The National Cancer Institute offers this grant to current NCI-funded research projects for interdisciplinary collaborations with the Patient-Derived Xenograft Development and Trial Centers Research Network (PDXNet) under the Beau Biden Cancer Moonshot Initiative. The grant aims to accelerate cancer research by improving pre-clinical evaluations of novel therapeutic concepts using PDX models, potentially leading to NCI-sponsored clinical trials. Eligible projects involve collaborations between non-PDXNet and PDXNet investigators within the scope of the parent grant. The deadline for applications is March 28, 2019.
Opportunity ID: 312428
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PA-19-174 |
| Funding Opportunity Title: | Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the PDX Development and Trial Centers Research Network (PDXNet) (Admin Supp Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.393 — Cancer Cause and Prevention Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jan 29, 2019 |
| Last Updated Date: | Jan 29, 2019 |
| Original Closing Date for Applications: | Mar 28, 2019 |
| Current Closing Date for Applications: | Mar 28, 2019 |
| Archive Date: | May 03, 2019 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities County governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) State governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Independent school districts Small businesses Native American tribal governments (Federally recognized) Private institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Special district governments City or township governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This administrative supplement funding opportunity announcement is part of the Beau Biden Cancer MoonshotSM Initiative to accelerate cancer research and was developed in response to a recommendation from the Blue Ribbon Panel of experts charged with advising the National Cancer Advisory Board on the exceptional scientific opportunities that could be accelerated through this initiative. As part of the Cancer Moonshot initiative, the National Cancer Institute (NCI) created the Patient-Derived Xenograft (PDX) Development and Trial Centers Research Network (PDXNet), a collaborative network of centers of excellence focused on using patient-derived xenografts and other patient-derived models to accelerate the development of NCI investigational new drug (IND) agents (i.e., those that the NCI is developing in collaboration with pharmaceutical partners) in NCI-sponsored early phase clinical trials. This FOA supports supplemental funds to current NCI-funded research projects for new interdisciplinary collaborations between non-PDXNet investigators and PDXNet investigators to perform research within the scientific scope(s) of the parent grant and/or cooperative agreement award(s) that will lead to improved pre-clinical evaluations of novel therapeutic concepts using the large-scale PDX model collections of PDXNet, and that could ultimately be tested in NCI-sponsored clinical trials. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PA-19-174.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-E-ADMINSUPP-RESEARCH | Use for R01, U01 and UM1 | PKG00247915 | Feb 28, 2019 | Mar 28, 2019 | View |
Package 1
Mandatory forms
312428 RR_SF424_2_0-2.0.pdf
312428 PHS398_CoverPageSupplement_4_0-4.0.pdf
312428 RR_OtherProjectInfo_1_4-1.4.pdf
312428 PerformanceSite_2_0-2.0.pdf
312428 RR_KeyPersonExpanded_2_0-2.0.pdf
312428 PHS398_ResearchPlan_4_0-4.0.pdf
312428 RR_Budget10_1_4-1.4.pdf
Optional forms
312428 RR_SubawardBudget10_30_1_4-1.4.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
